UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly 1 in 2,000 boys.UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly 1 in 2,000 boys.

About The Study: The findings of this case-control study show that soccer heading was associated with acute increases in blood biomarkers of neural damage, including dose-response relationships. These findings suggest that amateur-level heading may acutely affect neural integrity.

About The Study: This cohort study describes respiratory syncytial virus (RSV)-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSVpreF vaccination and nirsevimab during the 2024-2025 RSV season. 

About The Study: The findings of this study suggest that AI-enabled cardiopulmonary resuscitation (CPR) instruction shows promise for supporting bystanders. Further validation in diverse, general population settings is warranted to define the role of AI-based CPR instruction as a scalable public health intervention for out-of-hospital cardiac arrests. 

A new study led by researchers at the Harvard Pilgrim Health Care Institute, Boston University, Boston Medical Center, UMass Chan Medical School, and Brown University finds that children’s mental health concerns are appearing more often during routine visits with primary care doctors. Published in JAMA Network Open, the study shows a steady rise over the past decade, with especially large increases in visits related to anxiety.

Despite its popularity, researchers at São Paulo State University found no significant effects on inflammatory markers in the body after reviewing studies on the supplement.

Stefan Isaac, PhD, assistant professor of biochemistry and cell biology at Boston University Chobanian & Avedisian School of Medicine, has received a $2.1M Maximizing Investigators' Research Award (MIRA) (R35) from the NIH National Institute of General Medical Sciences (NIGMS) to fund his five-year project “Regulation of mitochondrial DNA packaging and gene expression.”

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma. In two studies published this month in Blood, the Journal of the American Society of Hematology, (doi.org/10.1182/blood.2025030891 and 10.1182/blood.2025030873) they found that using the drug mezigdomide (a cereblon E3 ligase modulator developed by Bristol Myers Squibb) can help these cells regain their strength and better destroy cancer by restoring the immune system’s ability to attack cancer and significantly improving the effectiveness of next-generation immunotherapies.